The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
The accelerated review covers WCK 5222 for multiple critical infections
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Applications include detailed scientific rationale and supporting clinical evidence
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Subscribe To Our Newsletter & Stay Updated
